Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EBT (2020 - 2025)

Historic EBT for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.

  • Xeris Biopharma Holdings' EBT rose 10325.78% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7616.47%. This contributed to the annual value of -$57.1 million for FY2024, which is 1007.81% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EBT is $621000.0, which was up 10325.78% from -$1.9 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' EBT's 5-year high stood at $621000.0 during Q3 2025, with a 5-year trough of -$50.8 million in Q4 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median EBT value was -$18.4 million (recorded in 2021), while the average stood at -$18.4 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' EBT crashed by 13237.41% in 2021, and later surged by 10325.78% in 2025.
  • Xeris Biopharma Holdings' EBT (Quarter) stood at -$50.8 million in 2021, then surged by 73.88% to -$13.3 million in 2022, then fell by 2.7% to -$13.6 million in 2023, then skyrocketed by 62.48% to -$5.1 million in 2024, then surged by 112.15% to $621000.0 in 2025.
  • Its EBT stands at $621000.0 for Q3 2025, versus -$1.9 million for Q2 2025 and -$9.2 million for Q1 2025.